Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
ChemMedChem ; 18(4): e202200599, 2023 02 14.
Artículo en Inglés | MEDLINE | ID: mdl-36533570

RESUMEN

Here we report the encapsulation of an osteosarcoma stem cell (OSC) potent gallium(III)-diflunisal complex 1 into polymeric nanoparticles, and its delivery into osteosarcoma cells. At the optimum feed (20 %, 1 NP20 ), nanoparticle encapsulation of 1 enhances potency towards bulk osteosarcoma cells and OSCs (cultured in monolayer and three-dimensional systems). Strikingly, the nanoparticle formulation exhibits up to 5645-fold greater potency towards OSCs than frontline anti-osteosarcoma drugs, doxorubicin and cisplatin. The nanoparticle formulation evokes a similar mechanism of action as the payload, which bodes well for future translation. Specifically, the nanoparticle formulation induces nuclear DNA damage, cyclooxygenase-2 downregulation, and caspase-dependent apoptosis. To the best of our knowledge, this is the first study to demonstrate that polymeric nanoparticles can be used to effectively deliver an OSC-active metal complex into osteosarcoma cells.


Asunto(s)
Neoplasias Óseas , Diflunisal , Galio , Nanopartículas , Osteosarcoma , Humanos , Diflunisal/farmacología , Micelas , Galio/farmacología , Línea Celular Tumoral , Osteosarcoma/tratamiento farmacológico , Polímeros/farmacología , Células Madre Neoplásicas
2.
Chembiochem ; 23(24): e202200532, 2022 12 16.
Artículo en Inglés | MEDLINE | ID: mdl-36281941

RESUMEN

We report the synthesis, characterisation, and anti-osteosarcoma properties of a gallium(III) complex (1) comprising of two 1,10-phenanthroline ligands and salicylate, a non-steroidal anti-inflammatory drug. The gallium(III) complex 1 displays micromolar potency towards bulk osteosarcoma cells and osteosarcoma stem cells (OSCs). Notably, the gallium(III) complex 1 exhibits significantly higher toxicity towards OSCs grown in monolayer and three-dimensional cultures than cisplatin, a frontline anti-osteosarcoma drug. Nuclei isolation and immunoblotting studies show that the gallium(III) complex 1 enters osteosarcoma cell nuclei and induces DNA damage. Flow cytometry and cytotoxicity studies (in the presence of prostaglandin E2) indicate that the gallium(III) complex 1 downregulates cyclooxygenase-2 (COX-2) expression and kills osteosarcoma cells in a COX-2-dependent manner. Further, the mode of osteosarcoma cell death evoked by the gallium(III) complex 1 is characterised as caspase-dependent apoptosis.


Asunto(s)
Antineoplásicos , Neoplasias Óseas , Galio , Osteosarcoma , Humanos , Fenantrolinas/farmacología , Galio/farmacología , Galio/uso terapéutico , Salicilatos/farmacología , Salicilatos/uso terapéutico , Ciclooxigenasa 2/metabolismo , Línea Celular Tumoral , Osteosarcoma/tratamiento farmacológico , Apoptosis , Células Madre/metabolismo , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...